within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CR02_AmoxicillinAndBetaLactamaseInhib;

model AmoxicillinAndBetaLactamaseInhib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.95,
    Cl = 3.416666666666667e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0218,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.015500000000000002,
    Tlag = 10.200000000000001);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>AmoxicillinAndBetaLactamaseInhibitor</td></tr><tr><td>ATC code:</td><td>J01CR02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A combination antibacterial medication consisting of amoxicillin, a broad-spectrum penicillin antibiotic, and a beta-lactamase inhibitor (commonly clavulanic acid), which extends the spectrum of amoxicillin by inhibiting bacterial beta-lactamase enzymes. It is approved and widely used today for the treatment of infections such as respiratory tract infections, urinary tract infections, skin infections, and others caused by susceptible bacteria.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single oral administration of amoxicillin in combination with clavulanic acid.</p><h4>References</h4><ol><li><p>Mellon, G, et al., &amp; Crémieux, AC (2020). Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. <i>The Journal of antimicrobial chemotherapy</i> 75(12) 3611–3618. DOI:<a href=\"https://doi.org/10.1093/jac/dkaa368\">10.1093/jac/dkaa368</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32888018/\">https://pubmed.ncbi.nlm.nih.gov/32888018</a></p></li><li><p>Schouwenburg, S, et al., &amp; Preijers, T (2025). A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta-Lactamase Inhibition. <i>Clinical pharmacology and therapeutics</i> 117(1) 193–202. DOI:<a href=\"https://doi.org/10.1002/cpt.3423\">10.1002/cpt.3423</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39205386/\">https://pubmed.ncbi.nlm.nih.gov/39205386</a></p></li><li><p>de Velde, F, et al., &amp; Mouton, JW (2016). Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. <i>The Journal of antimicrobial chemotherapy</i> 71(10) 2909–2917. DOI:<a href=\"https://doi.org/10.1093/jac/dkw226\">10.1093/jac/dkw226</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27330071/\">https://pubmed.ncbi.nlm.nih.gov/27330071</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01CR02 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AmoxicillinAndBetaLactamaseInhib;
